Primary Immunodeficiency Diseases clinical trials
The registry lists 211 studies for Primary Immunodeficiency Diseases across more than 10 countries. 51 are recruiting or about to start. 150 of them are mainly about Primary Immunodeficiency Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 6 narrower conditions too, such as Angioedemas, Hereditary: 529 studies, 97 open.
Get an email when these change. Save the Primary Immunodeficiency Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (16) · Baxalta now part of Shire (14) · CSL Behring (11) · Octapharma (10) · Takeda (9) · Grifols Therapeutics LLC (8) · Bio Products Laboratory (5) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (4)
What is being tested here
Drugs under test in Primary Immunodeficiency Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Alkylating agents 2 open · Antimetabolites 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases · Phase 3 · Octapharma
- Dec 2026Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) · Phase 3 · Kedrion S.p.A.
- Dec 2026Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients · Phase 3 · Virchow Group
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT · Paul Szabolcs
- Nov 2026PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Dec 2026Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection · New York Medical College
- Dec 2026Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) · New York Medical College
- Dec 2026EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection · New York Medical College
- Dec 2026Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) · New York Medical College
- Feb 2027COVID-19 in PID Survey · Imagine Institute
Who these studies take
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger. 28 (80%) take children under 18. 1 (3%) are for women only and 1 (3%) for men only; 11 (31%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 27 (77%) | 27 (77%) |
| 18 | 34 (97%) | 34 (97%) |
| 30 | 31 (89%) | 31 (89%) |
| 40 | 31 (89%) | 31 (89%) |
| 50 | 31 (89%) | 31 (89%) |
| 65 | 27 (77%) | 27 (77%) |
| 75 | 26 (74%) | 26 (74%) |
| 85 | 20 (57%) | 19 (54%) |
Across all 211 studies, recruiting or not: 49% stop at 75 or younger and 31% at 65; 82% take children; 1% are for women only and 2% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Primary Immunodeficiency Diseases studies take
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 35 mo19–41 · 25 studies | — | — |
| Observational | 72 mo30–… · 50 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- 25BT056: Basket Study of Viral Cytotoxic T LymphocytesOct 14, 2026NCT07873970
Studies
Recruiting first, then most recently updated. Showing 50 of 211. Browse all 211 → or search them.
- Detection and Characterization of Infections and Infection SusceptibilityRecruitingNCT004045601 country
- NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)RecruitingNCT05189925Phase 11 country
- Metabolic Profiling of Immune Responses in Immune-mediated DiseasesRecruitingNCT048648861 country
- NIAID Centralized Sequencing ProtocolRecruitingNCT032060991 country
- The Mechanistic Biology of Primary Immunodeficiency DisordersRecruitingNCT033940531 country
- Genetic Analysis of Immune DisordersRecruitingNCT000014671 country
- Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell DeathRecruitingNCT002468572 countries
- Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation DisordersEnrolling by invitationNCT008952711 country
- Pathogenic Study of Adult Immune EnteropathiesRecruitingNCT042805101 country
- Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary ImmunodeficienciesRecruitingNCT036108023 countries
- Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)RecruitingNCT03266640Phase 21 country
- EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV InfectionRecruitingNCT03266653Phase 21 country
- Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus InfectionRecruitingNCT03266627Phase 21 country
- Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene ProductsRecruitingNCT065197341 country
- 25BT056: Basket Study of Viral Cytotoxic T LymphocytesNot yet recruitingNCT07873970Early Phase 1
- Studies of Disorders With Increased Susceptibility to Fungal InfectionsRecruitingNCT012227411 country
- Knowledge of Inborn Errors of Immunity Among Pediatric PhysiciansNot yet recruitingNCT07837518
- COVID-19 in PID SurveyRecruitingNCT044596891 country
- A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With ImmunoglobulinsNot yet recruitingNCT07794735Phase 4
- A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyRecruitingNCT065650781 country
- Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of ImmunityRecruitingNCT061691501 country
- Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)RecruitingNCT066699491 country
- Exercise Intervention and ImmunodeficiencyRecruitingNCT07698197Not applicable1 country
- Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech RepublicAvailableNCT06955793
- TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in ChildrenRecruitingNCT04414046Phase 21 country
- Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant DiseasesNot yet recruitingNCT07660783Phase 21 country
- IVIG Boya: Safety, Efficacy, and PharmacokineticsNot yet recruitingNCT06150833Phase 3
- Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary ImmunodeficienciesRecruitingNCT027358241 country
- Pathophysiology of Inborn ImmunodeficienciesRecruitingNCT034226141 country
- Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)RecruitingNCT04197596Phase 1/21 country
- Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary ImmunodeficienciesNot yet recruitingNCT07526714
- Immunoglobulin Efficacy and Immune Profiling in Antibody ImmunodeficiencyNot yet recruitingNCT07516002
- Biologics And Clinical Immunology Cohort at SinaiRecruitingNCT047843641 country
- Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised HostsRecruitingNCT04691622Phase 11 country
- Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)RecruitingNCT07346859Phase 31 country
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT045283551 country
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 21 country
- Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related DisordersRecruitingNCT07261891Not applicable1 country
- Quality of Life Among Children With Inborn Error of ImmunityNot yet recruitingNCT07262047
- Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow FailuresRecruitingNCT04232085Phase 21 country
- Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID PatientsNot yet recruitingNCT07017036Phase 31 country
- Shwachman-Diamond Syndrome Global Patient Survey and Partnering PlatformRecruitingNCT069999541 country
- Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System DisordersRecruitingNCT067735461 country
- Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center StudyNot yet recruitingNCT06649643
- Recurrent Campylobacter Bacteraemia in Immunocompromised PatientsNot yet recruitingNCT064327771 country
- Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide RibosideNot yet recruitingNCT06324877Not applicable1 country
- Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIGNot yet recruitingNCT06089122Phase 3
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityRecruitingNCT06199427Phase 21 country
- Exercise Capacity, Physical Activity Level and Quality of Life in Children With Primary ImmunodeficiencyRecruitingNCT059994221 country
- Evaluating Bronchodilator Response in Patients With BronchiectasisRecruitingNCT05932316Not applicable1 country